PMID- 26422620 OWN - NLM STAT- MEDLINE DCOM- 20160714 LR - 20211203 IS - 1523-1755 (Electronic) IS - 0085-2538 (Linking) VI - 88 IP - 4 DP - 2015 Oct TI - Klotho upregulation by rapamycin protects against vascular disease in CKD. PG - 660-2 LID - 10.1038/ki.2015.223 [doi] AB - Medial arterial calcification involves chondrogenic/osteogenic transdifferentiation of vascular smooth muscle cells (VSMCs). Zhao et al. report that phosphate activates the mammalian target of rapamycin (mTOR) cascade in VSMCs, leading to downregulation of Klotho. Furthermore, rapamycin was shown to halt medial calcification. This effect was blunted in the absence of Klotho. Given the concomitant anti-atherosclerotic effects of the mTOR inhibitor, this agent has clinical potential as an inhibitor of intimal atherosclerosis and medial calcification. FAU - Hamano, Takayuki AU - Hamano T AD - Department of Comprehensive Kidney Disease Research, Osaka University Graduate School of Medicine, Osaka, Japan. LA - eng PT - Comment PT - Journal Article PL - United States TA - Kidney Int JT - Kidney international JID - 0323470 RN - 0 (Protein Kinase Inhibitors) RN - EC 2.7.11.1 (TOR Serine-Threonine Kinases) RN - EC 3.2.1.31 (Glucuronidase) RN - W36ZG6FT64 (Sirolimus) SB - IM CON - Kidney Int. 2015 Oct;88(4):711-21. PMID: 26061549 MH - Animals MH - Aorta, Abdominal/*drug effects MH - Aorta, Thoracic/*drug effects MH - Aortic Diseases/*prevention & control MH - Glucuronidase/*metabolism MH - Humans MH - Protein Kinase Inhibitors/*pharmacology MH - Sirolimus/*pharmacology MH - TOR Serine-Threonine Kinases/*antagonists & inhibitors MH - Vascular Calcification/*prevention & control EDAT- 2015/10/01 06:00 MHDA- 2016/07/15 06:00 CRDT- 2015/10/01 06:00 PHST- 2015/10/01 06:00 [entrez] PHST- 2015/10/01 06:00 [pubmed] PHST- 2016/07/15 06:00 [medline] AID - S2157-1716(15)32269-3 [pii] AID - 10.1038/ki.2015.223 [doi] PST - ppublish SO - Kidney Int. 2015 Oct;88(4):660-2. doi: 10.1038/ki.2015.223.